Zoetis Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Zoetis Inc. |
Ticker: | Ticker: ZTS |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). The investigation concerns whether Zoetis and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On April 12, 2024, Investor’s Business Daily published a report on Zoetis which alleged that Zoetis “stock crumbled Friday after a Wall Street Journal report suggested the company's arthritis shots, Librela and Solensia, sickened dogs and cats.” The Wall Street Journal article further reported that “[h]ealth regulators in the U.S. and Europe – which have received thousands of reports of side effects – are conducting reviews[]” and “Wall Street analysts have asked Zoetis about the pet owners’ complaints.” On this news, the price of Zoetis shares declined by $12.75 per share, or approximately 7.84%, from $162.73 per share on April 11, 2024 to close at $149.98 on April 12, 2024.
On April 12, 2024, Investor’s Business Daily published a report on Zoetis which alleged that Zoetis “stock crumbled Friday after a Wall Street Journal report suggested the company's arthritis shots, Librela and Solensia, sickened dogs and cats.” The Wall Street Journal article further reported that “[h]ealth regulators in the U.S. and Europe – which have received thousands of reports of side effects – are conducting reviews[]” and “Wall Street analysts have asked Zoetis about the pet owners’ complaints.” On this news, the price of Zoetis shares declined by $12.75 per share, or approximately 7.84%, from $162.73 per share on April 11, 2024 to close at $149.98 on April 12, 2024.